1887

Abstract

Complicated skin and soft tissue infections constitute a heterogeneous group of severe disorders, with surgical site infections being the most common hospital-acquired ones. The aim of our study was to investigate the synergistic and bactericidal activities of antimicrobial combinations of fosfomycin with rifampicin and tigecycline against , and methicillin-resistant (MRSA) clinical isolates, and also to evaluate their effects in a mouse wound infection model. In studies, the combinations of fosfomycin with rifampicin and tigecycline were both synergistic. These synergies were confirmed in studies: the drug combinations showed the highest antimicrobial effects compared to monotherapy. In conclusion, the efficacy of fosfomycin combinations, also confirmed in our model, may suggest new directions in the treatment of infected skin and a possible alternative way to control bacterial skin infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000649
2018-01-01
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/1/139.html?itemId=/content/journal/jmm/10.1099/jmm.0.000649&mimeType=html&fmt=ahah

References

  1. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011;377:228–241 [CrossRef][PubMed]
    [Google Scholar]
  2. Caínzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections-are they applicable today?. Clin Microbiol Infect 2008;14:9–18 [CrossRef][PubMed]
    [Google Scholar]
  3. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007;33:606–618 [CrossRef][PubMed]
    [Google Scholar]
  4. Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014;20:3–18 [CrossRef][PubMed]
    [Google Scholar]
  5. Robinson DA, Enright MC. Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3926–3934 [CrossRef][PubMed]
    [Google Scholar]
  6. Stefani S, Dowzicky M. Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Pharmaceuticals 2016;9:74 [CrossRef]
    [Google Scholar]
  7. European Centre for Disease Prevention and Control Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-net). 2013;http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf
  8. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10:266–278 [CrossRef][PubMed]
    [Google Scholar]
  9. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555–562 [CrossRef][PubMed]
    [Google Scholar]
  10. Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant Enterococcus in the health care setting. J Clin Microbiol 2016;54:2436–2447 [CrossRef][PubMed]
    [Google Scholar]
  11. Tiong JJL, Jse L, Mai CW. Global antimicrobial stewardship: a closer look at the formidable implementation challenges. Front Microbiol 1860;2016:7
    [Google Scholar]
  12. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64:i3–i10 [CrossRef][PubMed]
    [Google Scholar]
  13. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53:144–149 [CrossRef][PubMed]
    [Google Scholar]
  14. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65:iii35–iii44 [CrossRef][PubMed]
    [Google Scholar]
  15. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111–120 [CrossRef][PubMed]
    [Google Scholar]
  16. Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med 2017;7:a025262 [CrossRef][PubMed]
    [Google Scholar]
  17. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. 2015; CLSI document M100-S25
  18. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 7.1. 2017;www.eucast.org/clinical_breakpoints/
  19. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57:573–576 [CrossRef][PubMed]
    [Google Scholar]
  20. Rand KH, Houck HJ, Brown P, Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 1993;37:613–615 [CrossRef][PubMed]
    [Google Scholar]
  21. Poeppl W, Lingscheid T, Bernitzky D, Donath O, Reznicek G et al. Assessing pharmacokinetics of different doses of fosfomycin in laboratory rats enables adequate exposure for pharmacodynamic models. Pharmacology 2014;93:65–68 [CrossRef][PubMed]
    [Google Scholar]
  22. Simonetti O, Cirioni O, Cacciatore I, Baldassarre L, Orlando F et al. Efficacy of the quorum sensing inhibitor FS10 alone and in combination with tigecycline in an animal model of staphylococcal infected wound. PLoS One 2016;11:e0151956 [CrossRef][PubMed]
    [Google Scholar]
  23. Kugelberg E, Norström T, Petersen TK, Duvold T, Andersson DI et al. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 2005;49:3435–3441 [CrossRef][PubMed]
    [Google Scholar]
  24. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009;18:921–944 [CrossRef][PubMed]
    [Google Scholar]
  25. Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012;18:4–7 [CrossRef][PubMed]
    [Google Scholar]
  26. Kaye KS, Gales AC, Dubourg G. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. Int J Antimicrob Agents 2017;49:542–548 [CrossRef][PubMed]
    [Google Scholar]
  27. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004;53:928–935 [CrossRef][PubMed]
    [Google Scholar]
  28. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537–1541[PubMed]
    [Google Scholar]
  29. Mihailescu R, Furustrand Tafin U, Corvec S, Oliva A, Betrisey B et al. High activity of fosfomycin and rifampin against methicillin-resistant Staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2014;58:2547–2553 [CrossRef][PubMed]
    [Google Scholar]
  30. Wang J, Pan Y, Shen J, Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2017;16:24 [CrossRef][PubMed]
    [Google Scholar]
  31. Silvestri C, Cirioni O, Arzeni D, Ghiselli R, Simonetti O et al. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Eur J Clin Microbiol Infect Dis 2012;31:1759–1764 [CrossRef][PubMed]
    [Google Scholar]
  32. Simonetti O, Cirioni O, Lucarini G, Orlando F, Ghiselli R et al. Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation. J Antimicrob Chemother 2012;67:191–201 [CrossRef][PubMed]
    [Google Scholar]
  33. Tang HJ, Chen CC, Zhang CC, Su BA, Li CM et al. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis 2013;77:254–257 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000649
Loading
/content/journal/jmm/10.1099/jmm.0.000649
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error